Skip to Main Content

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery (START)

Conditions

Diseases of the Cardiovascular System

Phase II

What is the purpose of this trial?

The purpose of this study is to evaluate the effect of RBT-1 (stannous protoporphyrin [SnPP]/iron sucrose [FeS]) on preconditioning response biomarkers in subjects who are at risk for AKI following cardiac surgery.

  • Trial with
    Renibus Therapeutics, Inc.
  • Start Date
    10/06/2021
  • End Date
    06/30/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/10/2022
  • Study HIC
    #2000030910